Author

Stephanie Grabow

Vividion Therapeutics (United States)ORCID 0000-0003-0467-7871Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Aaron Nathan SneadiD· 2 shared Benjamin D. HorningiD· 2 shared David S. WeinsteiniD· 2 shared Eileen TraniD· 2 shared John J. SigleriD· 2 shared Jonathan PollockiD· 2 shared Justine LuiD· 2 shared Kenneth HeeiD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Aaron Nathan SneadORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer DiscoveryPeer-reviewedDec 19, 2025

Suppression of NRF2-dependent cancer growth by a covalent allosteric molecular glue

Nilotpal Roy, Tine L Wyseure, I‐Chung Lo…·Matthew P. Patricelli

This paper introduces VVD-065, a covalent NRF2 inhibitor that enhances NRF2 degradation and sensitizes tumors to therapy, supporting a Phase I clinical trial.

42 citationstop 1%

humanproteomics

𝕏 PostBluesky

Cancer BiologySciencePeer-reviewedOct 9, 2025

Covalent inhibitors of the RAS binding domain of PI3Ka impair tumor growth driven by RAS and HER2

Joseph E. Klebba, Nilotpal Roy, Steffen M. Bernard…·Matthew P. Patricelli

The paper develops covalent inhibitors targeting the RAS binding domain of PI3Kα, showing efficacy against RAS and HER2-driven tumors without affecting glucose homeostasis.

16 citationstop 4%

mouseexperimental assay

𝕏 PostBluesky